"Galaxy Gas": Learn more about the latest viral substance abuse trend. https://lnkd.in/ehb4vheH
About us
Psychiatric Times provides timely clinical, commentary, and practical cutting-edge content.. As the voice of psychiatry, Psychiatric Times’ premiere online and print content is written by and for mental health care physicians and professionals.
- Website
-
https://www.psychiatrictimes.com/
External link for Psychiatric Times
- Industry
- Media Production
- Company size
- 501-1,000 employees
- Headquarters
- Cranbury, NJ
- Type
- Privately Held
- Specialties
- mental health, psychiatry, health, and medicine
Locations
-
Primary
2 Clarke Drive
Suite 100
Cranbury, NJ 08512, US
Employees at Psychiatric Times
Updates
-
Mental health clinicians can help empower patients via tools like diet, including the MIND Diet. Mena Mirhom, MD, FAPA shares more on lifestyle and mental health. https://lnkd.in/gD943wZb
MIND Diet and Patient Empowerment
psychiatrictimes.com
-
Does reduced blood monitoring impact the detection of hematological abnormalities in clozapine-treated patients? Researchers performed a chart review study from the COVID-10 pandemic. https://lnkd.in/e3ivBJXv
Reduced Blood Monitoring and Hematological Abnormalities in Clozapine-Treated Patients
psychiatrictimes.com
-
Multiple sites are now enrolling participants in a phase 2 clinical trial to evaluate SPG302, the first synaptic regenerative therapy for schizophrenia. Psychiatric Times sat down with Peter Vanderklish, PhD, CSO at Spinogenix, Inc. to learn more about this new potential treatment option. https://lnkd.in/gYP3qgHq
First Synaptic Regenerative Therapy for Schizophrenia Under Investigation
psychiatrictimes.com
-
On September 26, 2024, the US Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride), formerly known as KarXT, for the treatment of schizophrenia in adults. In doing so, it represents the first drug with a novel mechanism in decades, as it selectively targets the M1 and M4 receptors without blocking D2 receptor. Although Psychiatric Times and other medical publications have reviewed the research leading to the approval, how prepared are clinicians to discuss the agent with patients and consider its use in regular practice?
This content isn’t available here
Access this content and more in the LinkedIn app
-
🔔 Stay ahead in psychiatry! The September issue of Psychiatric Times is out now. Each issue is packed with valuable information from top psychiatrists, ensuring you have the most current and relevant knowledge. Sign up today to receive your copy and never miss an update. Subscribe Here: https://ow.ly/iHqo50TvBvJ
-
What happens when your career, which usually brings you joy and gratitude, paradoxically becomes a source of great stress? https://lnkd.in/ejSKejHd
The Happiness Paradox of the Health Care Professional
psychiatrictimes.com
-
Psychiatric Times reposted this
Across the country, residents living in rural areas are struggling to address the growing mental health crisis. Rural communities face unique complexities that can exacerbate mental health challenges, from financial instability to social isolation to stigma around mental illness. Our industry can - and should - do more to provide mental health resources aligned specifically to these communities' needs. Rural Minds' founder and chairman Jeff Winton and I detail some of these opportunities in our recent piece in Psychiatric Times https://lnkd.in/ebshgxFS
Harnessing Digital Innovation: Addressing Mental Health Disparities in Rural America
psychiatrictimes.com
-
The context and timing of symptoms is critical for a timely and accurate bipolar diagnosis. Learn more in the latest Clinician's Corner column! Michael Asbach Autumn Roque, DNP, APRN, PMHNP-BC https://lnkd.in/gFxJKpQU
To Be or Not to Be? Understanding False Positives in Bipolar Diagnosis
psychiatrictimes.com
-
Breaking News: The US Food and Drug Administration approved a first in class agent for the treatment of schizophrenia in adults. Learn what Psychiatric Times' editor in chief John J. Miller, M.D. and other leaders in the field think about the Bristol Myers Squibb's #Cobenfy (formerly known as #KarXT) and how it will provide much-need help to patients with #schizophrenia.
FDA Approves Cobenfy, A First In-Class Agent for Schizophrenia
psychiatrictimes.com